Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model
Anirban Roy, Tatiana E. Koike, Aniket S. Joshi, Meiricris Tomaz da Silva, Kavya Mathukumalli, Mingfu Wu, Ashok Kumar
Anirban Roy, Tatiana E. Koike, Aniket S. Joshi, Meiricris Tomaz da Silva, Kavya Mathukumalli, Mingfu Wu, Ashok Kumar
View: Text | PDF
Research Article Muscle biology Therapeutics

Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model

  • Text
  • PDF
Abstract

Muscular dystrophies make up a group of genetic neuromuscular disorders that involve severe muscle wasting. TGF-β–activated kinase 1 (TAK1) is an important signaling protein that regulates cell survival, growth, and inflammation. TAK1 has been recently found to promote myofiber growth in the skeletal muscle of adult mice. However, the role of TAK1 in muscle diseases remains poorly understood. In the present study, we have investigated how TAK1 affects the progression of dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). TAK1 is highly activated in the dystrophic muscle of mdx mice during the peak necrotic phase. While targeted inducible inactivation of TAK1 inhibits myofiber injury in young mdx mice, it results in reduced muscle mass and contractile function. TAK1 inactivation also causes loss of muscle mass in adult mdx mice. By contrast, forced activation of TAK1 through overexpression of TAK1 and TAB1 induces myofiber growth without having any deleterious effect on muscle histopathology. Collectively, our results suggest that TAK1 is a positive regulator of skeletal muscle mass and that targeted regulation of TAK1 can suppress myonecrosis and ameliorate disease progression in DMD.

Authors

Anirban Roy, Tatiana E. Koike, Aniket S. Joshi, Meiricris Tomaz da Silva, Kavya Mathukumalli, Mingfu Wu, Ashok Kumar

×

Figure 8

TAK1 activation promotes myofiber growth in adult mdx mice.

Options: View larger image (or click on image) Download as PowerPoint
TAK1 activation promotes myofiber growth in adult mdx mice.
(A) Schemati...
(A) Schematic representation showing the age of mdx mice, time of AAVs injection, and euthanasia. (B) Representative photomicrographs of transverse muscle sections after performing H&E staining or immunostaining for laminin or Pax7 protein. Nuclei were counterstained with DAPI. Scale bar: 100 μm. (C–E) Average myofiber cross-section area, percentage of centronucleated fibers (CNFs), and percentage necrotic area in TA muscle of mdx mice injected with AAV6-GFP or a combination of AAV6-TAK1 and AAV6-TAB1. (F) Frequency of Pax7+ cells per unit area in TA muscle of mdx mice injected with AAV6-GFP or a combination of AAV6-TAK1 and AAV6-TAB1. n = 4 per group. (G and H) Western blot and densitometry analysis showing protein levels of p-eIF4E, eIF4E, p-rpS6, rpS6, p-TAK1, TAB1, TAK1, and unrelated protein GAPDH in TA muscle of mdx mice injected with AAV6-GFP or coinjected with AAV6-TAK1 and AAV6-TAB1. n = 3 per group. Data represented as mean ± SEM. *P ≤ 0.05, values significantly different from TA muscle of mdx mice injected with AAV6-GFP.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts